NEW YORK (GenomeWeb News) – After two hours of listening to oral arguments today, a judge in a US District Court in New York said that he will wait to make a decision on whether a case on the legality of the patenting of BRCA1 and BRCA2 genes by Myriad Genetics should be decided, or if it should go to trial or be dismissed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.